<DOC>
	<DOCNO>NCT00078481</DOCNO>
	<brief_summary>This study determine high amount idebenone take without harmful side effect child , teenager , adult Friedreich 's ataxia , progressive degenerative disease affect several body system . Studies France Canada show patient Friedreich 's ataxia take idebenone decrease size leave ventricle ( main pump chamber heart ) , often enlarged disease . It possible idebenone may also prevent progression nervous system degeneration Friedreich 's ataxia . Patients 5 year age old Friedreich 's ataxia may eligible study . Candidates screen blood test review medical record , include genetic study . Participants undergo follow procedure 6-day hospital admission NIH Clinical Center : - Placement intravenous catheter ( plastic tube insert vein ) collect blood sample drug administration - Blood urine test - Heart examination , include electrocardiogram ( EKG ) , assess heart function size . - Idebenone therapy : Patients take three tablet day ( 7 AM , 1 PM 7 PM ) day 2 , 3 4 hospitalization . Blood sample collect IV tube 0.5 , 1 , 2 , 4 , 6 hour first dose day 2 , 1 hour first third dos every day , 1 , 2 , 4 , 8 , 12 , 24 , 36 , 48 hour last dose day 4 determine body use eliminate drug . - Monitoring drug side effect : Patients frequent check vital sign ( blood pressure , pulse , temperature , breathe rate ) brief physical examination check drug side effect start drug therapy day 2 least 43 hour last dose day 4 . Patients experience difficulty discharge hospital sixth day 1-month supply medication take 3 time day home . They contact phone every 2 week take medication check side effect . Blood test also do every 2 week check abnormality .</brief_summary>
	<brief_title>Phase 1 Trial Idebenone Treat Patients With Friedreich 's Ataxia</brief_title>
	<detailed_description>Background : Friedreich 's ataxia ( FRDA ) progressive , autosomal recessive , multisystem degenerative disease currently effective treatment . Recent study demonstrate lipid-soluble antioxidant lead modest reversal cardiomyopathy patient FRDA . It possible antioxidant may also prevent progression neurodegeneration . Objective : This phase 1B , unblinded trial examine toxicity tolerability antioxidant idebenone give multiple-dose regimen short inpatient course long term patient FRDA . Study Population : We aim enroll 15 patient divide evenly among three age cohort : child ( age 5-11 ) , adolescent ( age 12-17 ) , adult ( age great equal 18 ) . Design : Our primary objective examine tolerability idebenone give dose 60 mg/kg/day 72 hour ( total 9 dos ) inpatient set ( NIH Clinical Center ) . This dose maximum dose examine ( 75 mg/kg/day ) well tolerate dose-limiting toxicity ( DLT ) phase 1A ( protocol # 01-N-0167 ) study . The 72 hour course represent 5.5 half-lives drug base upon previous study drug healthy human subject phase 1A data , thereby allow serum concentration drug reach steady-state level . This multiple dose regimen allow u examine accumulation drug examine tolerability drug steady-state concentration . The patient follow inpatient monitoring additional 43 hour , represent 3.3 half-lives , allow relatively complete elimination drug . If adverse event note inpatient phase trial , patient resume take drug outpatient basis 1 month determine long-term tolerability compliance . Outpatients follow phone interview NIH research team along routine blood work every 2 week . Our secondary objective document pharmacokinetics , specifically apparent distribution volume ( Vd ) , elimination half-life ( t1/2 ) , elimination clearance ( CLE ) , steady-state concentration ( CSS ) idebenone inpatient phase study . Outcome Parameters : Outcomes phase I trial type frequency adverse event , , compliance dose regimen . Our secondary endpoint pharmacokinetics dose regimen . Future Directions : We hope follow phase I study multicenter , double-blinded , placebo-controlled phase III trial use ataxia scale develop FRDA primary endpoint .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis FRDA confirm FRDA mutation . Age great equal five year . No exposure idebenone coenzyme Q ( 10 ) period least one week onset medication phase study . Written , inform consent ( assent , applicable ) . EXCLUSION CRITERIA : History hypersensitivity reaction idebenone coenzyme Q ( 10 ) . Pregnant lactating woman . All woman childbearing potential must negative serum pregnancy prior medication phase study . If minor positive pregnancy test , inform inform parent unless ask minor . Lactose intolerant individual ( lactose content tablet ingredient ) . Age less five year old . Platelet count , lymphocyte count hemoglobin lower limit normal . Alkaline phosphatase , SGOT , SGPT great 1.5 x upper limit normal . Bilirubin great 1.2 g/dl . Creatinine great 1.5 x upper limit normal . Clinically significant medical disease , judgment investigator , would expose patient undue risk harm prevent patient complete study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Neurodegeneration</keyword>
	<keyword>Anti-Oxidant</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Hereditary</keyword>
	<keyword>Spinocerebellar</keyword>
	<keyword>Friedreich Ataxia</keyword>
	<keyword>FRDA</keyword>
</DOC>